For the quarter ended September 2025, Xeris Biopharma (XERS Quick QuoteXERS - Free Report) reported revenue of $74.38 million, up 37.1% over the same period last year. EPS came in at $0, compared to -$0.06 in the year-ago quarter.

The reported revenue represents a surprise of +0.04% over the Zacks Consensus Estimate of $74.35 million. With the consensus EPS estimate being $0.01, the EPS surprise was -100%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Revenue- Gvoke: $25.15 million versus the three-analyst average estimate of $26.22 million.
• Product Revenue- Keveyis: $11.94 million compared to the $36.23 million average estimate based on three analysts.
• Revenue- Royalty, contract and other: $0.32 million versus $1.58 million estimated by three analysts on average.
• Revenue- Product revenue, net: $74.06 million versus $73.01 million estimated by three analysts on average.
• Product Revenue- Recorlev: $36.98 million versus the three-analyst average estimate of $10.55 million.

View all Key Company Metrics for Xeris Biopharma here>>>

Shares of Xeris Biopharma have returned +20.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.